VHL inactivation, which mediates the over-expression of VEGF in approximately 80% of ccRCC patients, causes VEGF and its receptor to be interesting targets for novel RCC treatment strategies [37–39]. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.